Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma

2 Nov 2014

Abstract excerpt

Histone deacetylases (HDAC) control gene expression through their ability to acetylate proteins, thereby influencing a diverse range of cellular functions. Class I HDAC (HDAC1-3 and 8) and HDAC6 are predominantly upregulated in malignancies and their altered expression in some cancers has a significant prognostic implication. The expression and prognostic consequence of dysregulated Class I HDAC and HDAC6, key...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25482492
DOI: 10.4161/15592294.2014.983367

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myelomaPMID 25482492Read ↗

The biological significance of histone modifiers in multiple myeloma: clinical applicationsSemantic proximity Read ↗

Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectivesSemantic proximity Read ↗

Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myelomaSemantic proximity Read ↗

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitorsSemantic proximity Read ↗

The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myelomaSemantic proximity Read ↗

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cellsSemantic proximity Read ↗

Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic ModificationsSemantic proximity Read ↗

Epigenetic Aberrations in Multiple MyelomaSemantic proximity Read ↗

Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma TherapySemantic proximity Read ↗

Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?Semantic proximity Read ↗

KDM6A regulates immune response genes in multiple myelomaSemantic proximity Read ↗

Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic targetSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.